Last reviewed · How we verify

Parecoxib and remifentanil

Ullevaal University Hospital · FDA-approved active Small molecule

Parecoxib and remifentanil is a COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) Small molecule drug developed by Ullevaal University Hospital. It is currently FDA-approved for Perioperative pain management and analgesia, Postoperative pain relief. Also known as: Dynastat.

Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation.

Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation. Used for Perioperative pain management, Postoperative analgesia.

At a glance

Generic nameParecoxib and remifentanil
Also known asDynastat
SponsorUllevaal University Hospital
Drug classCOX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil)
TargetCOX-2 (parecoxib); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Parecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby decreasing pain and inflammation without affecting platelet function. Remifentanil is a synthetic opioid that binds to mu-opioid receptors in the central nervous system, providing rapid onset and offset analgesia and sedation due to its ester metabolism. Together, they provide multimodal analgesia for perioperative pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Parecoxib and remifentanil

What is Parecoxib and remifentanil?

Parecoxib and remifentanil is a COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) drug developed by Ullevaal University Hospital, indicated for Perioperative pain management and analgesia, Postoperative pain relief.

How does Parecoxib and remifentanil work?

Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation.

What is Parecoxib and remifentanil used for?

Parecoxib and remifentanil is indicated for Perioperative pain management and analgesia, Postoperative pain relief.

Who makes Parecoxib and remifentanil?

Parecoxib and remifentanil is developed and marketed by Ullevaal University Hospital (see full Ullevaal University Hospital pipeline at /company/ullevaal-university-hospital).

Is Parecoxib and remifentanil also known as anything else?

Parecoxib and remifentanil is also known as Dynastat.

What drug class is Parecoxib and remifentanil in?

Parecoxib and remifentanil belongs to the COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) class. See all COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) drugs at /class/cox-2-selective-inhibitor-parecoxib-and-opioid-agonist-remifentanil.

What development phase is Parecoxib and remifentanil in?

Parecoxib and remifentanil is FDA-approved (marketed).

What are the side effects of Parecoxib and remifentanil?

Common side effects of Parecoxib and remifentanil include Nausea, Vomiting, Hypotension, Respiratory depression, Dizziness, Headache.

What does Parecoxib and remifentanil target?

Parecoxib and remifentanil targets COX-2 (parecoxib); mu-opioid receptor (remifentanil) and is a COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil).

Related